Target Name: LOC100507336
NCBI ID: G100507336
Review Report on LOC100507336 Target / Biomarker Content of Review Report on LOC100507336 Target / Biomarker
LOC100507336
Other Name(s): uncharacterized LOC100507336 | LOC100507336 variant variant X1 | Uncharacterized LOC100507336, transcript variant X1

LOC100507336: A Drug Target / Disease Biomarker

LOC100507336 is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the LOC100 family of proteins, which are known for their role in intracellular signaling. LOC100507336 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

The LOC100 family of proteins is characterized by the presence of a unique N-terminal region that consists of a long amino acid sequence known as the N-terminal hypervariable region (N-VIP). This region is involved in various cellular processes, including cell signaling, protein-protein interactions, and intracellular signaling. LOC100507336 is no exception to this general rule, as it also has a N-terminal VIP-like region that is involved in intracellular signaling.

One of the key functions of LOC100507336 is its role in intracellular signaling. This protein is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival. It is also involved in the regulation of inflammation, fibrosis, and other cellular processes that are relevant to various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

In addition to its role in intracellular signaling, LOC100507336 is also known for its potential as a drug target or biomarker. Several studies have suggested that LOC100507336 may be a potential drug target for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

For example, LOC100507336 has been shown to be involved in the regulation of various cellular processes that are relevant to cancer, including cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). Therefore, LOC100507336 has been identified as a potential drug target for cancer.

In addition to its potential as a cancer drug target, LOC100507336 has also been shown to be involved in the regulation of neurodegenerative diseases. This protein is involved in the regulation of various cellular processes that are relevant to neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Therefore, LOC100507336 has also been identified as a potential drug target for neurodegenerative diseases.

Finally, LOC100507336 has also been shown to be involved in the regulation of cardiovascular diseases. This protein is involved in the regulation of various cellular processes that are relevant to cardiovascular diseases, including blood pressure, cholesterol, and blood vessel function. Therefore, LOC100507336 has also been identified as a potential drug target for cardiovascular diseases.

In conclusion, LOC100507336 is a protein that is expressed in various tissues of the body and is involved in various cellular processes that are relevant to cancer, neurodegenerative diseases, and cardiovascular diseases. As a result, LOC100507336 has been identified as a potential drug target or biomarker for these diseases, and further research is needed to determine its full role in these processes.

Protein Name: Uncharacterized LOC100507336

The "LOC100507336 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC100507336 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC100507346 | LOC100507351 | LOC100507389 | LOC100507412 | LOC100507424 | LOC100507443 | LOC100507513 | LOC100507520 | LOC100507547 | LOC100507577 | LOC100507656 | LOC100509646 | LOC100533709 | LOC100630923 | LOC100652743 | LOC100652768 | LOC100652833 | LOC100652999 | LOC100653061 | LOC100996385 | LOC100996412 | LOC100996583 | LOC100996637 | LOC100996643 | LOC100996664 | LOC100996770 | LOC101060017 | LOC101060106 | LOC101060179 | LOC101060400 | LOC101060445 | LOC101060524 | LOC101060632 | LOC101448202 | LOC101593348 | LOC101926887 | LOC101926948 | LOC101926953 | LOC101926959 | LOC101926969 | LOC101927002 | LOC101927020 | LOC101927025 | LOC101927026 | LOC101927040 | LOC101927053 | LOC101927060 | LOC101927066 | LOC101927082 | LOC101927108 | LOC101927143 | LOC101927164 | LOC101927166 | LOC101927169 | LOC101927179 | LOC101927188 | LOC101927199 | LOC101927216 | LOC101927243 | LOC101927245 | LOC101927253 | LOC101927263 | LOC101927269 | LOC101927314 | LOC101927369 | LOC101927394 | LOC101927421 | LOC101927476 | LOC101927483 | LOC101927495 | LOC101927518 | LOC101927531 | LOC101927548 | LOC101927550 | LOC101927571 | LOC101927588 | LOC101927598 | LOC101927605 | LOC101927609 | LOC101927627 | LOC101927636 | LOC101927668 | LOC101927712 | LOC101927727 | LOC101927741 | LOC101927745 | LOC101927770 | LOC101927787 | LOC101927825 | LOC101927827 | LOC101927834 | LOC101927840 | LOC101927853 | LOC101927855 | LOC101927857 | LOC101927863 | LOC101927896 | LOC101927897 | LOC101927910 | LOC101927932